Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
318 patients with 759 BMs were enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The clinical-radiomic model (EGFR-RS + EGFR mutation status + BM size) outperformed the clinical model in identifying high-risk lesions with local recurrence (discovery: P < 0.001; HR = 4.54; test: P = 0.002; HR = 5.1). [CONCLUSION] The multimodal EGFR-RS, demonstrating better consistency than the WF-RS, effectively predicted the local recurrence of NSCLC BMs.
[INTRODUCTION] Limited linkage between epidermal growth factor receptor (EGFR) mutations and recurrence-predictive radiomic signatures restricts the application of radiomics-guided therapy for brain m
- p-value P < 0.001
- p-value P = 0.01
- HR 2.13
APA
Hsu CY, Tsai HH, et al. (2025). Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases.. European journal of radiology, 193, 112420. https://doi.org/10.1016/j.ejrad.2025.112420
MLA
Hsu CY, et al.. "Multimodal radiomic analysis to determine high-Consistency prognostic phenotypes associated with epidermal growth factor receptor mutations in non-small cell lung cancer brain metastases.." European journal of radiology, vol. 193, 2025, pp. 112420.
PMID
41016079 ↗
Abstract 한글 요약
[INTRODUCTION] Limited linkage between epidermal growth factor receptor (EGFR) mutations and recurrence-predictive radiomic signatures restricts the application of radiomics-guided therapy for brain metastases (BMs) from non-small-cell lung cancer (NSCLC). This study aimed to establish an EGFR-associated radiomic signature (EGFR-RS), compare its consistency with that of conventional whole radiomic features-based radiomic signature (WF-RS), and evaluate its efficacy in predicting local recurrence for BMs treated with radiosurgery.
[METHODS] Brain magnetic resonance (MR) and computed tomography (CT) images of NSCLC patients with BMs undergoing radiosurgery between 2008 and 2020 were examined. The least absolute shrinkage and selection operator was utilized to select features and develop signatures. Discriminative abilities were assessed using the area under the curve, while univariable and multivariable competing risk regression determined predictors and established a clinical-radiomic model.
[RESULTS] In total, 318 patients with 759 BMs were enrolled. The EGFR-RS, incorporating 11 MR and six CT EGFR-associated prognostic radiomic features, displayed better consistency, and superior predictive performance than the WF-RS, with C-indices of 0.746 (95 %CI 0.616, 0.876) in the test cohort, compared with 0.655 (95 %CI 0.527, 0.784) for the WF-RS. Multivariable analysis indicated EGFR-RS as the sole significant predictor of local recurrence in both the discovery and test sets (P < 0.001, hazard ratio [HR] = 2.75; and P = 0.01, HR = 2.13, respectively). The clinical-radiomic model (EGFR-RS + EGFR mutation status + BM size) outperformed the clinical model in identifying high-risk lesions with local recurrence (discovery: P < 0.001; HR = 4.54; test: P = 0.002; HR = 5.1).
[CONCLUSION] The multimodal EGFR-RS, demonstrating better consistency than the WF-RS, effectively predicted the local recurrence of NSCLC BMs.
[METHODS] Brain magnetic resonance (MR) and computed tomography (CT) images of NSCLC patients with BMs undergoing radiosurgery between 2008 and 2020 were examined. The least absolute shrinkage and selection operator was utilized to select features and develop signatures. Discriminative abilities were assessed using the area under the curve, while univariable and multivariable competing risk regression determined predictors and established a clinical-radiomic model.
[RESULTS] In total, 318 patients with 759 BMs were enrolled. The EGFR-RS, incorporating 11 MR and six CT EGFR-associated prognostic radiomic features, displayed better consistency, and superior predictive performance than the WF-RS, with C-indices of 0.746 (95 %CI 0.616, 0.876) in the test cohort, compared with 0.655 (95 %CI 0.527, 0.784) for the WF-RS. Multivariable analysis indicated EGFR-RS as the sole significant predictor of local recurrence in both the discovery and test sets (P < 0.001, hazard ratio [HR] = 2.75; and P = 0.01, HR = 2.13, respectively). The clinical-radiomic model (EGFR-RS + EGFR mutation status + BM size) outperformed the clinical model in identifying high-risk lesions with local recurrence (discovery: P < 0.001; HR = 4.54; test: P = 0.002; HR = 5.1).
[CONCLUSION] The multimodal EGFR-RS, demonstrating better consistency than the WF-RS, effectively predicted the local recurrence of NSCLC BMs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Non-Small-Cell Lung
- Female
- Lung Neoplasms
- ErbB Receptors
- Male
- Brain Neoplasms
- Middle Aged
- Mutation
- Prognosis
- Aged
- Magnetic Resonance Imaging
- Tomography
- X-Ray Computed
- Phenotype
- Multimodal Imaging
- Retrospective Studies
- Radiosurgery
- Adult
- Neoplasm Recurrence
- Local
- Radiomics
- Brain metastases
… 외 3개
같은 제1저자의 인용 많은 논문 (5)
- Innovative approaches to irinotecan-based therapies for glioblastoma: Advancements in drug delivery and combination strategies.
- Metabolic adaptation in colorectal cancer microenvironment: Focus on cancer-associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs).
- Disrupting immune silence: Noncoding RNAs targeting the programmed cell death protein 1/programmed cell death ligand 1 axis in tumor immunity.
- Chitosan-functionalized mesoporous silica nanoparticles co-loaded with chrysin and quercetin: a potent strategy against lung cancer cells.
- Melanoma and its fibroblastic allies: the emerging importance of CAFs in immune suppression, ECM modulation, and therapy resistance.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.